Related Experiment Video
Updated: May 24, 2026
10:30
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test
Yvonne Y B Liu1, Peter Rigsby, Dorothea Sesardic
1Division of Bacteriology, National Institute for Biological Standards and Control, Health Protection Agency, South Mimms, Hertfordshire, UK.
Analytical Biochemistry
|March 13, 2012
Summary
This study introduces a novel assay to specifically detect active botulinum type A toxin. It distinguishes functional toxin from inactive forms, offering a realistic alternative to existing methods.
Area of Science:
- Biochemistry
- Immunology
- Neuroscience
Background:
- Conventional ELISAs and protease activity assays cannot differentiate active botulinum type A toxin from inactive or denatured forms.
- Existing methods lack specificity for the biologically active toxin molecule, limiting accurate potency assessment.
Purpose of the Study:
- To develop a highly sensitive and precise immunobiochemical assay for detecting only the active form of botulinum type A toxin.
- To create an assay that correlates with in vivo potency and serves as a realistic alternative to current methods.
Main Methods:
- Co-coating microtiter plates with SNAP25 substrate and an antibody targeting a conformational epitope on the toxin's Hc domain.
- Utilizing a chaotropic agent to isolate functional toxin, followed by buffer conditions that activate the captured toxin.
- Employing a neoepitope antibody to quantify cleaved SNAP25 substrate, indicating active toxin presence.
Main Results:
- The new assay demonstrates high sensitivity (130 aM Limit of Detection) and precision (1.4% Geometric Coefficient of Variation).
- The assay specifically detects intact, active botulinum type A toxin, showing no reactivity with denatured or fragmented forms.
- Demonstrated correlation with in vivo potency, validating the assay's biological relevance.
Conclusions:
- This novel assay is the first immunobiochemical method capable of specifically quantifying biologically active botulinum type A toxin.
- The assay provides a realistic and accurate alternative for assessing botulinum toxin activity and potency.
